{"schema":"hottub-news/list/v1","item_schema":"hottub-news/item/v1","count":4,"sponsored":0,"items":[{"id":"n_72cxtp2ly7uogdwtdisq","seq":842178,"kind":"article","title":"タグリッソの重大な副作用に「再生不良性貧血」追加","url":"https://medical-tribune.co.jp/news/articles?blogid=7&entryid=616448","summary":"厚生労働省は昨日（9月29日）付で医薬局医薬安全対策課長通知（医薬安発0929第1号）を発出。「重大な副作用」の項に①第三世代EGFRチロシンキナーゼ阻害薬（EGFR-TKI）のオシメルチニブ（商品名タグリッソ）は「再生不良性貧血」を、②複数の免疫チェックポイント阻害薬（ICI）は「重度の胃炎、食道炎」を、③インターロイキン（IL）-6阻害薬のトシリズマブ（アクテムラ他）は「薬剤性過敏症症候群」を...","published":"2026-09-30T07:02:54Z","seen":"2026-09-30T07:02:54Z","lang":"en","source":{"id":"kite-medical-tribune-co-jp-14fcf3","name":"medical-tribune.co.jp","domain":"medical-tribune.co.jp"},"via":"kite-medical-tribune-co-jp-14fcf3","topics":["medicine","@mtn（読売）,@mtn（j&j）,@mtn（武田薬品工業）,@提供記事,整…"],"entities":[{"id":"Q29006526","name":"Tagrisso","type":"other"}],"image":"https://asset.mtweb.jp/media/2026/06/02185852/25_Tenbunkaitei.jpg","story":"st_72cxtp2ly7uogdwtdisq","category":"health","category_p":0.84,"sentiment":"negative","tone":-0.82,"political":0.09},{"id":"n_ccd3td3vj2jspe7z7dgq","seq":793431,"kind":"article","title":"'타그리소' 약효 떨어진 폐암에…AZ·허치메드, 병용치료 美 허가신청","title_en":"'Tagrisso' effectiveness declines in lung cancer... AZ and Hutchmed apply for combination therapy approval in the US","url":"https://www.medipana.com/news/articleView.html?idxno=418445","summary":"아스트라제네카와 허치메드가 \\'타그리소\\' 치료 후 진행한 폐암에 두 경구 표적치료제를 병용하는 전략으로 미국 허가에 도전한다. 기존 EGFR 표적치료에 내성이 생긴 환자 가운데 MET 이상이 확인된 환자를 겨냥한 치료법이다. 허치메드는 29일 아스트라제네카(AstraZeneca, AZ)가 \\'오파티스\\'(ORPATHYS·성분명 사볼리티닙)와 \\'타그리소\\'(오시머티닙) 병용요법의 신약허가신청서(NDA)를 미국 식품의약국(FDA)에 제출했다고 밝혔다. 신청 대상은 EGFR 티로신키나아제 억제제(TKI) 치료 중 또는 치료 후 질병이 진행하고,","published":"2026-09-29T22:40:46Z","seen":"2026-09-30T00:15:49Z","lang":"ko","source":{"id":"kite-cdn-medipana-com-912f9c","name":"cdn.medipana.com","domain":"cdn.medipana.com"},"via":"kite-cdn-medipana-com-912f9c","topics":["medicine","파마시안"],"authors":["최봉선 기자"],"entities":[{"id":"Q731938","name":"AstraZeneca","type":"org"},{"id":"Q113510355","name":"Hutchison MediPharma Limited","type":"org"},{"id":"Q29006526","name":"Tagrisso","type":"other"}],"story":"st_ccd3td3vj2jspe7z7dgq","category":"health","category_p":0.69,"sentiment":"negative","tone":-0.27,"political":0.15},{"id":"n_nxr576v5fa3xk4ym2hna","seq":608944,"kind":"article","title":"Submission of US NDA for ORPATHYS® plus TAGRISSO | Company Announcement","url":"https://www.investegate.co.uk/announcement/rns/hutchmed-china-limited--hcm/submission-of-us-nda-for-orpathys-plus-tagrisso/9795286","published":"2026-09-29T07:45:00Z","seen":"2026-09-29T07:50:19Z","lang":"en","country":"GB","source":{"id":"investegate.co.uk","name":"investegate.co.uk","domain":"investegate.co.uk"},"via":"gdelt-gkg-english","topics":["health","economy","business","politics"],"authors":["Investegate"],"entities":[{"id":"Q29006526","name":"Tagrisso","type":"other"}],"story":"st_nxr576v5fa3xk4ym2hna","category":"economy-business","category_p":0.71,"sentiment":"neutral","tone":-0.01,"political":0.04},{"id":"n_wdjnjte2pqofirsl4mfa","seq":555223,"kind":"article","title":"HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer","url":"https://www.manilatimes.net/2026/09/29/tmt-newswire/globenewswire/hutchmed-announces-submission-of-us-nda-for-orpathys-plus-tagrisso-in-met-driven-egfr-mutated-lung-cancer/2434594","published":"2026-09-29T00:03:00Z","seen":"2026-09-29T01:37:58Z","lang":"en","source":{"id":"manilatimes.net","name":"manilatimes.net","domain":"manilatimes.net","outlet":{"wikidata":"Q1573100","name":"The Manila Times","type":"magazine","country":"PH","designations":["organization","periodical"]}},"via":"gdelt-gkg-english","topics":["economy","politics","business","health"],"entities":[{"id":"Q113510355","name":"Hutchison MediPharma Limited","type":"org"},{"id":"Q29006526","name":"Tagrisso","type":"other"}],"story":"st_3fql2tu6i4ezck7fz7ya","category":"health","category_p":0.63,"sentiment":"neutral","tone":-0.02,"political":0.16}]}